Search results
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
AOL· 3 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update their formulas for fall doses, in an attempt to target the KP.2 strain ...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks· 3 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared ...
What is COVID KP.3 variant? Symptoms, CDC data, what to know about the newest COVID strain
USA Today· 7 days agoThe Centers for Disease Control and Prevention said it is tracking the new COVID variant KP.3 as data shows its dominance across the United States. For the two-week period starting on May 26 ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 6 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Moderna director Afeyan sells over $30 million in company stock By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) Director Noubar Afeyan has sold a significant number of company shares,...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 4 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....
FDA recommends COVID jab manufacturers update formulas to combat new strain
BizPac Review· 3 days agoA new strain of COVID has prompted recommendations for vaccine companies to update their formulas in anticipation of cases in the fall. The U.S. Food and Drug Administration ...
Analysis | Court rejects abortion pill challenge, but what happens next?
Washington Post· 4 days agoWhat do you think is next in the fight over medication abortion? Today’s edition: Senate Republicans...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 6 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...